CyGenics Acquires Stake in DNAPro in Exchange for Cell Sciences Subsidiary
Disposes of wholly owned subsidiary, Cell Sciences, in exchange for 20% stake in DNAPro
"We have long wanted to tap into the growing healthcare sector in Malaysia," said Steven Fang, Group CEO, CyGenics. "DNAPro is the partner we have been looking for. Our exchange of Cell Sciences for a minority interest in DNAPro, is expected to provide an improved return, partially from the synergies generated. Further, this transaction allows us to better focus on our core revenue generating activity of cord blood banking, which has seen annual growth in excess of 70%."
It is further expected that this arrangement will provide the CyGenics group, which will have a representative on DNAPro's board, with enhanced access to the Malaysian healthcare markets, and enable cross-selling and licensing of DNAPro's products via CyGenics' international network. CyGenics now has a business presence in Australia, Hong Kong, China, India, Indonesia, the Netherlands, the Philippines, Malaysia, Singapore, Thailand, the UK and the US.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.